Lacuna

System Health & Monitoring

Live API checks plus the measurement-layer census: quality grades, withheld metrics, vintage gaps, and display provenance.

System Health

API endpoint monitoring and latency tracking

0

Healthy

0

Degraded

0

Down

-

Avg Latency

Service	Status	Latency	Last Check
Dataset API	Checking...	-	-
ClinicalTrials.gov	Checking...	-	-
Build Status	Checking...	-	-

Developer Note: Health checks run automatically every 60 seconds. ClinicalTrials.gov has a rate limit of 10 requests/second.

Data Pipeline Status

Counts and grades from verified artifacts — no fabricated latency or invented completion percentages.

59

Verified deals

150

Company records

12 days since last update

Dataset as of 2026-09-20

SEC EDGAR ingest

Not configured (static dataset)

Not configured

Source-quality grades

Companies avg 63.9 · deals avg 86.7

Provenance instrumentation

21 / 899 (2.3%)

SEC operating revenue

MeshIC audit found issuer/CIK identity mismatches in the prior artifact. The stale records were removed rather than left available to downstream analysis. Regenerate with scripts/fetch-sec-revenue.ts, which now validates SEC registrant identity before accepting facts.

Withheld

Operating growth rates

SEC revenue evidence is currently withheld pending identity-validated regeneration. Financing-derived and valuation-derived rates are not substituted for operating growth.

Withheld

CMS utilization

No verified CMS aggregate observations are committed. Sector reimbursement totals stay null rather than using mean-payment fallback arithmetic.

Withheld

Dataset version v9. Grades and coverage come from computed-data-quality-scores.json and provenance-baseline.json, hash-verified on every push. SEC ingest uses live loadSummaryPipelines when LACUNA_DATA_MODE=db.

Measurement layer

Quality grades, gated-metric publication, vintage gaps, and display provenance — read from computed artifacts, not a hardcoded pipeline panel.

Published (7/7 fully provenanced)

Withheld of 221 (96.8%)

Missing dedicated as-of (66/135)

Uncovered display sites of 899

Company source quality

avg

A 3B 39C 42D 58F 8

Deal source quality

avg

A 26B 5C 23D 1F 4

/47 computedPremium rows exactly reproducible · Deal values use announcement date only (50/50) — not a value vintage. · Pre-deal valuations with date: 49/49.

Most uncovered numeric render files

src/components/NetworkAnalysisHonest.tsx90
src/components/WhiteSpaceAnalysis.tsx86
src/components/StrategicPositioningMap.tsx61
src/app/sections/PayerOpsPage.tsx49
src/components/FairnessAuditV2.tsx46
src/components/CompetitiveAnalysisDashboard.tsx33
src/components/FounderCharacteristics.tsx33
src/components/GenderInferenceQuality.tsx26

Artifact v9 · hash a6ef9998a42f · 2026-09-20T00:00:00.000Z · 66 companies and 5 deals graded D/F

Reimbursement & Commercial Due Diligence

Verified deal context by sector from the curated dataset — no invented TAM, payer mix, or keyword risk scores. The SA051 card is an investigation target, not a payment conclusion.

Investigation target — not decision-grade. Phase 1 seeds a source-traceable question. No payment, RVU, or practice-level exposure is asserted. Missing inputs are not treated as zero.

SA051 pelvic-exam supply-pack lineage

How would a change in a practice-expense supply input propagate through affected services, PE RVU, fee-schedule payment, and utilization — if those inputs are later source-verified?

Status: machine_proposed
Publishable: no
Sources
Rate rows

Source · open
Which public CMS file and vintage control SA051 metadata?
PE input · open
Is SA051 a practice-expense supply input for that vintage?
Affected services · open
Which services include SA051 in PE inputs, if any, for that vintage?
PE RVU · open
How would a verified SA051 input change flow into PE RVU?
Payment mechanics · open
Which explicit PFS inputs convert PE RVU into a fee-schedule payment?
Utilization question · open
What utilization and payment assumptions would be required before modeling practice-level exposure?

Reviewer path: source verified → specialist reviewed → approved. Code numbers and Lacuna labels only unless CPT content is licensed.

Verified deal context by sector

Descriptive counts from dataset.verified.json only. Deals join on target company id and sector — not name substring. TAM/SAM, reimbursement risk scores, and payer-mix estimates are not shown.

Companies

Verified deals

Disclosed values

Median deal ($M)

—

No verified acquisitions tagged to this sector in the dataset.

Catalyst watchlist

Weekly biopharma calendar joined to Lacuna's verified acquirer and company ids. Dates are scheduled PDUFA/readout marks with an actual date when the decision already happened.

Women's-health relevant

6 of 62 weekly catalysts are tagged women's-health relevant. The current feed is general biopharma; Lacuna IDs are filled only when the company is already in the verified universe.

Scheduled	Company	Event	Status	Basis
2026-09-04actual 2026-09-04	AstraZenecaEtcamah (camizestrant)	approvalESR1-mutated HR+/HER2- advanced or metastatic breast cancer	approved	actual_event · dayBreast Health
2026-09-10actual 2026-09-10	AbbVieatogepant (QULIPTA/AQUIPTA)	readoutpreventive treatment of menstrual migraine	positive	actual_event · dayTherapeutics
2026-09-17actual 2026-09-17	Biosimilar Collaborations Irelandpertuzumab biosimilar (Pebrilzo)	CHMPHER2-positive early and metastatic breast cancer	positive	actual_event · dayBreast Health
2026-09-17actual 2026-09-17	Corcept Therapeuticsrelacorilant (Lifyorli)	CHMPplatinum-resistant high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, with nab-paclitaxel	positive	actual_event · dayTherapeuticsNCT05257408
2026-09-17actual 2026-09-17	SFL Pharmaceuticals Deutschlandsenaparib (Sepalna)	CHMPmaintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	positive	actual_event · dayTherapeutics
2027-04-01	Organon/Sebela Women's HealthMIUDELLA (copper intrauterine system)	PDUFAprevention of pregnancy - extension of duration of use to 6 years	upcoming	company_guidance · quarteracquirer-organon · Contraception

Tracked acquirers / companies · next 90 days

2 scheduled events in 2026-10-02 → 2026-12-31 for Roche, J&J, GRAIL, or another verified id.

Scheduled	Company	Event	Status	Basis
2026-10-09	RocheTecentriq (atezolizumab)	PDUFAstage III colon cancer	upcoming	third_party_calendar · dayacquirer-roche
2026-10-15	RocheEnspryng (satralizumab)	PDUFAthyroid eye disease	upcoming	third_party_calendar · dayacquirer-roche

Acquirer Fit & Precedent Map

Verified acquirer profiles and same-sector historical deals beside a company. Historical exits are not an acquisition prediction, and a missing price is not zero.

Historical profile overlap only. Derived from 51 verified deals (45 disclosed, 2 with funding multiples) across 99 companies. Per-sector aggregates require n≥5; disclosed-only values carry selection bias. Acquirer profiles built from 38 verified acquirers and 51 deals.

Research integrity: context on this panel is not a score, a valuation, an acquisition prediction, or a market census.

Lacuna does not turn report context into a company score.
Lacuna does not turn a gap into a valuation.
Lacuna does not turn historical exits into an acquisition prediction.
Lacuna does not turn research representation into clinical validation.
Lacuna does not turn a qualitative expert assessment into an objective metric.
Lacuna does not turn unavailable data into 0.
Lacuna does not turn unknown into a negative finding.
Lacuna does not turn a static curated sample into a market census.
Lacuna does not turn AI opportunity framing into an AI performance claim.
Lacuna does not turn a polished dashboard into evidence that does not exist.

These outputs are deterministic, descriptive comparisons built from a curated public-source sample. They are not fitted predictive models, calibrated acquisition probabilities, company valuations, or investment recommendations.

Select Company to Analyze

Companies with historical profile overlap

Company	Sector	Profile overlap	Context figure
Evvy	diagnostics	Myriad Genetics	$375M
Contraline	digital health	Hologic	$178M
Alloy	menopause	Bayer	$350M
Béa Fertility	fertility	CooperSurgical (CooperCompanies)	$534M
Granata Bio	fertility	CooperSurgical (CooperCompanies)	$534M
Gesynta Pharma	fertility	CooperSurgical (CooperCompanies)	$534M
Testmate Health	diagnostics	Myriad Genetics	$375M
Juniper Genomics	diagnostics	Myriad Genetics	$375M
Aria CV	digital health	Hologic	$178M
Attn: Grace	pelvic health	Medtronic	$350M
Bone Health Technologies	digital health	Hologic	$178M
Cat Health	digital health	Hologic	$178M
Chronicle Bio	digital health	Hologic	$178M
Clear Gene	diagnostics	Myriad Genetics	$375M
Everly Health	diagnostics	Myriad Genetics	$375M
FemDx Medsystems	digital health	Hologic	$178M
Frontier Bio	digital health	Hologic	$178M
Future Family	fertility	CooperSurgical (CooperCompanies)	$534M
Gameto	digital health	Hologic	$178M
Harmony Nutrition	digital health	Hologic	$178M
Hera Biotech	diagnostics	Myriad Genetics	$375M
Inherent Biosciences	diagnostics	Myriad Genetics	$375M
Lighthouse Pharma	digital health	Hologic	$178M
Madorra	digital health	Hologic	$178M
Mercy Bio	diagnostics	Myriad Genetics	$375M
Mirvie	diagnostics	Myriad Genetics	$375M
Nest Collaborative	maternal health	CooperSurgical (CooperCompanies)	$350M
Neuspera	digital health	Hologic	$178M
NowDx	diagnostics	Myriad Genetics	$375M
Proov (portfolio)	fertility	CooperSurgical (CooperCompanies)	$534M
Sana Health	digital health	Hologic	$178M
Siren	digital health	Hologic	$178M
Solace Therapeutics	digital health	Hologic	$178M
Toi Labs	digital health	Hologic	$178M
Veana Therapeutics	digital health	Hologic	$178M
Willow	maternal health	CooperSurgical (CooperCompanies)	$350M
Xandar Kardian	digital health	Hologic	$178M
xCures	digital therapeutics	Hologic	$178M
YourChoice Therapeutics	fertility	CooperSurgical (CooperCompanies)	$534M
X-Therma	digital health	Hologic	$178M
AOA Dx	diagnostics	Myriad Genetics	$375M
Cadence OTC	fertility	CooperSurgical (CooperCompanies)	$534M
Cirqle	digital health	Hologic	$178M
Eli Health	diagnostics	Myriad Genetics	$375M
Novocuff	maternal health	CooperSurgical (CooperCompanies)	$350M
Ocon Med	fertility	CooperSurgical (CooperCompanies)	$534M
Raydiant Oximetry	maternal health	CooperSurgical (CooperCompanies)	$350M
Vitra Labs	fertility	CooperSurgical (CooperCompanies)	$534M

Export & share

Download the verified dataset in JSON, CSV, or Parquet.

Data Export

Download the verified dataset in multiple formats for analysis

99

Companies

51

Acquisitions

38

Acquirers

Dataset Schema: Companies (id, name, sector, stage, description, funding), Acquisitions (id, target, acquirer, value, announcedDate, closedDate, strategicRationale).

Version: v9 · Updated: 2026-09-20

Developer Tools

API documentation, SDK references, code examples, and integration guides for engineers building on the Lacuna platform.

Developer Tools

API documentation, SDK references, and code examples for engineers

API Reference

REST API documentation for dataset access

API

Dataset JSON

Direct access to verified dataset in JSON format

API

Python API (FastAPI + GraphQL)

Local sidecar — REST, OpenAPI, and GraphQL for dataset + trials (port 8000)

API

.NET API (ASP.NET Core + EF)

Local sidecar — REST, Swagger, and EF Core for dataset + research studies (port 8001)

API

GitHub Repository

Source code, issues, and contribution guidelines

Repo

MODEL_CARD.md

Methodology and limitations for Exit Similarity Explorer scoring

Docs

ClinicalTrials.gov API

NIH clinical trial search API v2 documentation

API

Engineering Note: All API endpoints are versioned and follow REST conventions. The dataset is immutable between releases — check the provenance field for version and last-updated timestamps.